Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Severe case -509% Improvement Relative Risk Schmidt et al. Remdesivir for COVID-19 LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? PSM retrospective 477 patients in the USA (March 2020 - February 2021) Higher severe cases with remdesivir (p=0.000015) Schmidt et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.34330 Favors remdesivir Favors control
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19
Schmidt et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.34330
Schmidt et al., Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and.., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.34330
Nov 2021   Source   PDF  
  All Studies   Meta
Retrospective 1,106 prostate cancer patients, showing higher mortality with remdesivir treatment.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
This study includes HCQ and remdesivir.
risk of severe case, 509.0% higher, OR 6.09, p < 0.001, treatment 43, control 434, adjusted per study, propensity score matching, multivariable, RR approximated with OR, excluded in exclusion analyses: confounding by indication is likely and adjustments do not consider COVID-19 severity at baseline.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Schmidt et al., 12 Nov 2021, retrospective, USA, peer-reviewed, 42 authors, study period 17 March, 2020 - 11 February, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperRemdesivirAll
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19
MD Andrew L Schmidt, MD Matthew D Tucker, MD Ziad Bakouny, MD Chris Labaki, PhD; Chih-Yuan Hsu, PhD; Yu Shyr, MD Andrew J Armstrong, MD Tomasz M Beer, MD Ragneel R Bijjula, MD Mehmet A Bilen, MD Cindy F Connell, Scott Joseph Dawsey, MD Bryan Faller, MD Xin Gao, MD Benjamin A Gartrell, MD David Gill, MD Shuchi Gulati, PhD Susan Halabi, MD Clara Hwang, MD Monika Joshi, MD Ali Raza Khaki, MD Harry Menon, MD Michael J Morris, MD Matthew Puc, MD Karen B Russell, MD Dimpy P Shah, PhD Neil J Shah, MD Nima Sharifi, MD Justin Shaya, MD Michael T Schweizer, MD; John Steinharter, MD Elizabeth M Wulff-Burchfield, MD Wenxin Xu, MD Jay Zhu, PhD Sanjay Mishra, PhD Petros Grivas, PhD Brian I Rini, MD Jeremy Lyle Warner, MD Tian Zhang, MD Toni K Choueiri, MD Shilpa Gupta, MD Rana R Mckay, Aakash Desai, Aaron M Cohen, Adam J Olszewski, Aditya Bardia, Ahmad Daher, Alaina J Brown, Albert Yeh, Albert Hsiao, Alex Cheng, Alice Y Zhou, Alicia Beeghly-Fadiel, Alicia K Morgans, Alokkumar Jha, Alvaro G Menendez, Alyson Fazio, Amanda Nizam, Amelie G Ramirez, Amit A Kulkarni, Amit K Verma, Amro Elshoury, Andrea Verghese Rivera, Andrew Walden, Andrew J Piper-Vallillo, Andrew L Cook, Ang Li, Angela Shaw Cantrell, Angelo Cabal, Anju Nohria, Anne H Angevine, Anthony P Gulati, Antonio Giordano, Anup Kasi, Archana Ajmera, Arielle Elkrief, Ariffa Kariapper, Arturo Loaiza-Bonilla, Asha Jayaraj, Astha Thakkar, Atlantis D Russ, Babar Bashir, Balazs Halmos, Barbara B Logan, Barbara R Wood, Becky Slawik, Becky Dixon, Benjamin French, Bertrand Routy, Blanche H Mavromatis, Brandon Hayes-Lattin, Briana Barrow Mccollough, Bridget Fleissner, Brittany Stith, Camille P Wicher, Candice Schwartz, Carey C Thomson, Carmen C Solorzano, Carolina Granada, Carrieann Brown, Cassandra Hennessy, Catherine Stratton, Cecilia A Castellano, Celina Ang, Chaitanya Mandapakala, Chen-Pin Wang, Chinmay Jani, Chris Su, Christian F Misdary, Christina Chapman, Christopher Mcnair, Christopher A Lemmon, Christopher L Geiger, Christopher R Friese, Christopher T Su, Cindy Mckeown, Claire Hoppenot, Clarke A Low, Clement Pillainayagam, Cristiano Ferrario, Crosby D Rock, Cyndi Gonzalez Gomez, Cynthia Masson, Daniel Mundt, Daniel Addison, Daniel B Flora, Daniel G Stover, Daniel H Kwon, Daniel J Hausrath, Daniel W Bowles, Daniel Y Reuben, Danielle Shafer, Danielle S Bitterman, Darciann O' Sullivan, Daruka Mahadevan, Davendra P S Sohal, David Whaley, David A Slosky, David D Chism, Dawn L Hershman, Deborah B Doroshow, Deepak Ravindranathan, Dimitrios Farmakiotis, Divaya Bhutani, Donald C Vinh, Dory A Freeman, Douglas B Johnson, Edward Hatton, Eliezer M Van Allen, Elizabeth A Griffiths, Elizabeth J Davis, Elizabeth S Nakasone, Elizabeth T Loggers, Elizabeth V Robilotti, Ellis Levine, Elwyn C Cabebe, Emily Hsu, Emily Powell, Eneida R Nemecek, Eric Lau, Eric B Durbin, Eric H Bernicker, Eric J Small, Erin Cook, Erin A Gillaspie, Erin G Reid, Esperanza B Papadopoulos, Eyob Tadesse, Firas H Wehbe, Gary H Lyman, Gary K Schwartz, Gayathri Nagaraj, Genevieve Boland, George D Demetri, Gerald Batist, Gerald Gantt Jr., Goetz Kloecker, Grace Shaw, Gregory J Riely, Hala T Borno, Haneen Saker, Hannah Dzimitrowicz, Heather H Nelson, Hina Khan, Hira G Shaikh, Hyma V Polimera, James L Chen, Jamie Stratton, Jared D Acoba, Jaymin M Patel, Jean M Connors, Jeff Mather, Jeffrey P Henderson, Jennifer Dill, Jennifer Girard, MD Jeremy L Warner, Jerome J Graber, Jesse Papenburg, Jessica Altman, Jessica E Hawley, Jessica M Clement, Ji (janie) Park, Jian Li Campian, John Philip, John F Deeken, Jonathan Riess, Jonathan E Rosenberg, Jonathan M Loree, Jonathon (jack) W Senefeld, Jordan Kharofa, Jorge A Garcia, Joshua D Palmer, Judy T Lewis, Julie Guido, Julie C Fu, Julie Tsu-Yu Wu, Jun Yang Jiang, Justin F Gainor, Justin F Klamerus, K M Steve Lo, Kanishka G Patel, Karen De Cardenas, Karen Vega-Luna, Karen J Goldsmith, Karla Hansen, Kathryn E Huber, Keith E Stockerl-Goldstein, Kelly J Jeffords, Kent F Hoskins, Kerry L Reynolds, Kim Cerrone, Kimberly Cortez, Kyle T Enriquez, Lane R Rosen, Latoya N Lashley, Lauren D Pomerantz, Laurie J Smith, Lawrence E Feldman, Leslie A Fecher, Leyre Zubiri, Li C Liu, Lidia Schapira, Lisa Tachiki, Lisa B Weissmann, Lori J Rosenstein, Lucy L Wang, Maggie Tomasini, Maheen Abidi, Mahir Khan, Mansi R Shah
JAMA Network Open, doi:10.1001/jamanetworkopen.2021.34330
IMPORTANCE Androgen deprivation therapy (ADT) has been theorized to decrease the severity of SARS-CoV-2 infection in patients with prostate cancer owing to a potential decrease in the tissuebased expression of the SARS-CoV-2 coreceptor transmembrane protease, serine 2 (TMPRSS2). OBJECTIVE To examine whether ADT is associated with a decreased rate of 30-day mortality from SARS-CoV-2 infection among patients with prostate cancer.
Conflict of Interest Disclosures: Dr Bakouny reported grants from Genentech/imCORE; nonfinancial support from Bristol Myers Squibb; and personal fees from UpToDate outside the submitted work. Dr Shyr reported grants from the National Cancer Institute during the conduct of the study. Dr Armstrong reported grants from Bayer, Janssen, and Pfizer/Astellas; and personal fees from Bayer, Janssen, and Pfizer/Astellas outside the submitted work. Dr Beer reported grants paid to his institution from Alliance Foundation Trials, Astellas Pharma, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Endocyte Inc, Freenome, Grail Inc, Harpoon Therapeutics, Janssen Research and Development, Medivation Inc, Sotio, Theraclone Sciences/OncoResponse, and Zenith Epigenetics; personal fees from Arvinas, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squib, Clovis Oncology, Constellation, GlaxoSmithKline, Grail Inc, Janssen, Merck & Co, Myovant Sciences, Novartis, Pfizer, Sanofi, and Tolero; and stock ownership in Arvinas Inc and Salarius Pharmaceuticals outside the submitted work. Dr Bilen reported grants to his institution from AAA, AstraZeneca, Bayer, Bristol Myers Squibb, Genentech/Roche, Genome and Company, Incyte, Nektar, Peloton Therapeutics, Pfizer, SeaGen, Tricon Pharmaceuticals, and Xencor outside the submitted work; and personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Calithera Biosciences, Eisai, EMD Serono, Exelixis, Genomic Health, Janssen, Nektar, Pfizer, Sanofi,..
Abidi, Aboulafia, Accordino, 19 and Cancer Consortium. A systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance, Cancer Cell, doi:10.1016/j.ccell.2020.10.022
Acquisition, Schmidt, Tucker, Bakouny, Labaki et al., Critical revision of the manuscript for important intellectual content
Administrative, Tucker, Labaki, Armstrong, Dawsey et al., None
Author, Shyr, Schmidt, Tucker, Bakouny et al., access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis
Baratchian, Mcmanus, Berk, Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes, Sci Rep, doi:10.1038/s41598-021-90491-1
Bhopal, Bhopal, Sex differential in COVID-19 mortality varies markedly by age, Lancet, doi:10.1016/S0140-6736(20)31748-7
Butterworth, Mcclellan, Allansmith, Influence of sex in immunoglobulin levels, Nature, doi:10.1038/2141224a0
Chalmers, Burns, Ebot, Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions, Prostate Cancer Prostatic Dis, doi:10.1038/s41391-020-00314-z
Crawford, Heidenreich, Lawrentschuk, Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations, Prostate Cancer Prostatic Dis, doi:10.1038/s41391-018-0079-0
Dai, Liu, Liu, Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak, Cancer Discov
Deng, Rasool, Russell, Natesan, Asangani, Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19, iScience, doi:10.1016/j.isci.2021.102254
Dhindsa, Zhang, Mcphaul, Association of circulating sex hormones with inflammation and disease severity in patients with COVID-19, JAMA Netw Open, doi:
Grivas, Khaki, Wise-Draper, Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium, Ann Oncol, doi:10.1016/j.annonc.2021.02.024
Harris, Taylor, Minor, The REDCap Consortium: building an international community of software platform partners, J Biomed Inform, doi:10.1016/j.jbi.2019.103208
Harris, Taylor, Thielke, Payne, Gonzalez et al., Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform, doi:10.1016/j.jbi.2008.08.010
Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Klein, Li, Milinovich, Androgen deprivation therapy in men with prostate cancer does not affect risk of infection with SARS-CoV-2, J Urol, doi:10.1097/JU.0000000000001338
Kuderer, Choueiri, Shah, Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, Lancet, doi:10.1016/S0140-6736(20)31187-9
Lee, Cazier, Angelis, UK Coronavirus Monitoring Project Team. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study, Lancet, doi:10.1016/S0140-6736(20)31173-9
Li, Han, Dai, Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide, Nat Commun, doi:10.1038/s41467-021-21171-x
Lin, Ferguson, White, Prostate-localized and androgen-regulated expression of the membranebound serine protease TMPRSS2, Cancer Res
Lucas, Heinlein, Kim, The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis, Cancer Discov, doi:10.1158/2159-8290.CD-13-1010
Ming, Rosenbaum, Substantial gains in bias reduction from matching with a variable number of controls, Biometrics, doi:10.1111/j.0006-341X.2000.00118.x
Montopoli, Zumerle, Vettor, Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532), Ann Oncol, doi:10.1016/j.annonc.2020.04.479
Patel, Zhong, Liaw, Does androgen deprivation therapy protect against severe complications from COVID-19?, Ann Oncol, doi:10.1016/j.annonc.2020.06.023
Peckham, De Gruijter, Raine, Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission, Nat Commun, doi:10.1038/s41467-020-19741-6
Pettersson, Graff, Bauer, The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis, Cancer Epidemiol Biomarkers Prev, doi:10.1158/1055-9965.EPI-12-0042
Qiao, Wang, Mannan, Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2021450118
Samuel, Majd, Richter, Androgen signaling regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men, Cell Stem Cell, doi:10.1016/j.stem.2020.11.009
Von Elm, Altman, Egger, Pocock, Gøtzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Ann Intern Med, doi:10.7326/0003-4819-147-8-200710160-00010
Westblade, Brar, Pinheiro, SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19, Cancer Cell, doi:10.1016/j.ccell.2020.09.007
Wise-Draper, Desai, Elkrief, Rini, Flora et al., Mixing Parameter of 1 (LASSO) eTable 6. Results of Regression Analysis for 30-Day Mortality Between ADT + Chemotherapy Compared to ADT, Adjusting for the Variables Selected by the Elastic-Net Regularization With a Mixing Parameter of 1 (LASSO) eFigure 1. Patient Selection eFigure 2. Loss of Dead30 Events (All Cause 30-Day Mortality) and Standardized Mean Difference of Propensity Scores Between the 2 ADT Groups (on ADT and Not on ADT) eFigure 3. Distributions of Propensity Scores of Patients on ADT and Not on ADT Before and After Matching SUPPLEMENT 2, doi:10.1016/j.annonc.2020.08.2312
Zhu, Zhang, Wang, China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, doi:10.1056/NEJMoa2001017
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop